Skip to main
DMAA
DMAA logo

DMAA Market Capitalization Overview

Market Cap: $342.21M as of Jul 11, 2025

$342.21M
Past Month+$235.87M (221.78%)
As of Jul 11, 2025, DMAA has a market capitalization of $342.21M. Over the past 30 days, its market cap has increased by 221.94%, while in the last 12 months, it has increased by .

Market capitalization represents the total value of Drugs Made In America Acquisition Corp as perceived by the stock market. It is calculated by multiplying the current stock price by the total number of outstanding shares.

DMAA Market Cap Formula = Stock Price * Shares Outstanding

The market cap of DMAA helps investors assess the company's size and compare it with competitors for better investment decisions.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

DMAA Market Cap History

DateMarket CapChange
Jul 1, 2025$341.71M+221.94%
Jun 2, 2025$106.14M+0.59%
May 1, 2025$105.52M+0.60%
Apr 1, 2025$104.89M+0.70%
Mar 3, 2025$104.16M-64.15%
Feb 25, 2025$290.55M

DMAA End of Year Market Cap History

DateMarket CapChange
2025$342.21M

FAQs About Drugs Made In America Acquisition Corp (DMAA) Market Cap

As of Jul 11, 2025, the market capitalization of DMAA is $342.21M. Market cap represents the total value of a company’s outstanding shares and is a key indicator of its size in the stock market.

In the last 30 days, Drugs Made In America Acquisition Corp’s market capitalization has increased by 221.78%, changing from $106.35M to $342.21M as of Jul 11, 2025.

In the last 3 months, Drugs Made In America Acquisition Corp’s market capitalization has increased by —, changing from – to – as of –.

In the year –, Drugs Made In America Acquisition Corp’s market capitalization increased from – in January to – in December, reflecting a — change.

Drugs Made In America Acquisition Corp (DMAA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.